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Abstract— Enantiomerically pure carbamate-monoprotected trans-cyclohexane-1,2-diamines are used as chiral organocatalysts for the 
addition of aryl ketones and acetone to nitroalkenes leading to enantioenriched β-substituted γ-nitroketones. The reaction is performed in 
the presence of 3,4-dimethoxybenzoic acid as additive, in chloroform as solvent at room temperature, achieving enantioselectivities up to 
96%. Theoretical calculations are used to justify the observed sense of the stereoinduction.  
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1. Introduction 
The enantioselective preparation of γ-nitrocarbonyl 
compounds is an interesting synthetic topic nowadays, as 
they are precursors of important compounds such as 
alkaloids,1 aminoacids,2 antitumorals,3 antibiotics,4 
peptidomimetics,5 and marine metabolites6, among 
others.7 The direct conjugate addition of carbonyl 
compounds to conjugated nitroalkenes by means of metal-
free organic catalysts represents a convenient access to 
this type of compounds. Therefore, over the past years, 
much progress has been made in the development of 
organocatalytic-based methodologies for accomplishing 
this task.8  
Nonetheless, the direct organocatalytic asymmetric 
conjugate addition of aromatic ketones to nitroalkenes 
still is considered a “difficult” process much less 
explored. Thus, the enantioselective addition of aromatic 
ketones to β-nitrostyrenes is particularly interesting, as the 
corresponding γ-nitroketones can be used as intermediates 
in the preparation of β-arylated γ-aminobutyric acids, 
which are pharmacologically important GABAB agonists.9 
Commercial examples are baclofen,10 used in the 
treatment of spasticity, or phenibut,11 a tranquilizer and 
nootropic drug.   
Although the enantioselective addition of particular 
aryl ketones, such as acetophenone, to β-nitrostyrene has 
been described using proline12 or proline-derived 
organocatalysts,13 most of the reported procedures using 
arylated ketones and nitroalkenes involve the use of chiral 
primary amine-containing  NH-functionalized species, 
such as amides,14 sulfonamides15 and thioureas,16 the last 
ones achieving the best results. Using these primary 
amine-containing bifunctional organocatalysts, the 
enantioselectivity is induced by addition of a transient 
enamine to the nitroolefin, which is hydrogen bond-
coordinated by the NH group of the additional 
functionality.  
We have recently reported the use of primary amines 
from chiral trans-cyclohexane-1,2-diamines 1-3, 
monosubstituted with the common Boc, Cbz, and Fmoc 
protecting groups, respectively, as organocatalysts in the 
enantioselective  Michael addition reaction of aldehydes 
to maleimides.17 Is this paper we present the use of these 
simple primary amine-containing species as chiral 
organocatalysts in the conjugate addition reaction of 
arylated ketones, or even acetone, to nitroalkenes, leading 
to enantioenriched β-substituted γ-nitroketones. 
Theoretical calculations have been used to explain the 
observed sense of enantioselectivity.  
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2. Results and discussion 
The carbamate-monoprotected primary amines 1-3 
employed as organocatalysts in this study were prepared 
by monoprotection of (1S,2S)-cyclohexane-1,2-diamine 
with the common tert-butoxycarbonyl (Boc), 
benzyloxycarbonyl (Cbz) and fluorenylmethoxycarbonyl 
(Fmoc) groups as previously reported.17b The search for 
the most appropriate organocatalyst and reaction 
conditions (Table 1) began using the model conjugate 
addition reaction of acetophenone (4a) (2 equiv) to (E)-β-
nitrostyrene (5a), organocatalyzed by 1 (20 mol%) in 
toluene as solvent at room temperature, which afforded 
the corresponding adduct (R)-6aa in 62% isolated yield 
and with a 88% ee after 5 d reaction time (Table 1, entry 
1). The (R) absolute configuration of the final adduct was 
determined by comparison of the elution order of the 
corresponding enantiomers in chiral HPLC with those in 
the literature.16c This adduct (R)-6aa is a precursor of the 
drug baclofen.16h 
When the Cbz-monoprotected diamine 2 was used as 
organocatalyst under these reaction conditions, the 
enantioselectivy of the process remained unchanged, 
although the isolated yield of the final adduct diminished 
(Table 1, entry 2). In addition, when the Fmoc-
monoprotected primary amine 3 was employed, the 
enantioselectivity was lowered down to 68% (Table 1, 
entry 3). Therefore, we choose the Boc-containing 
primary amine 1 as organocatalyst for the rest of the 
study.  
The use of others solvents was also explored. Thus, 
dichloromethane and chloroform were attempted, the last 
one raising slightly both yield and enantioselectivity 
(Table 1, entries 4 and 5), whereas the use of hexane or 
ether diminished both values (Table 1, entries 6 and 7). In 
addition, a polar solvent such as DMF afforded only a 
50% ee of (R)-6aa, and a protic one such as water proved 
not beneficial (Table 1, entries 8 and 9). Moreover, the 
use of a combination of DMF/water (2/1, v/v), a solvent 
mixture that has proven effective in the enantioselective 
conjugate addition of aldehydes to maleimides 
organocatalyzed by 1,17 gave a poor enantioselection 
(Table 1, entry 10).     
We then explore the effect of the addition of some 
additives to the reaction, employing chloroform as the 
reaction solvent. Thus, the addition of the basic imidazole 
(20 mol%), something that proved beneficial in some 
conjugate addition reactions,18 was detrimental for the 
enantioselectivity in this case, compared to when no 
additive was used (Table 1, compare entries 5 and 11). 
Therefore, we switched to the use of carboxylic acids as 
additives (20 mol%), as it is known that they can facilitate 
the interconversion of the different intermediates of the 
catalytic enamine cycle.8g; 19 Thus, the addition of benzoic 
acid (20 mol%) resulted in a slight improvement of yield 
and enantioselectivity compared to when  no additive was 
used (Table 1, compare entries 5 and 12). This positive 
result prompted us to explore if a modulation of the pKa 
of the additive by changing the substituent in the aromatic 
ring could be beneficial.   
 
 
Table 1. Screening and optimization of the reaction conditions for the enantioselective addition reaction of acetophenone to (E)-β-nitrostyrene. 
 
Entry Catalyst (mol%) Additive (mol%)a Solvent T  (ºC) Yield (%)a ee (%)b 
1 1 (20) - PhMe 25 62 88 (R) 
2 2 (20) - PhMe 25 55 88 (R) 
3 3 (20) - PhMe 25 60 68 (R) 
4 1 (20) - CH2Cl2 25 63 87 (R) 
5 1 (20) - CHCl3 25 65 89 (R) 
6 1 (20) - Hexane 25 58 86 (R) 
7 1 (20) - Et2O 25 50 82 (R) 
8 1 (20) - DMF 25 60 50 (R) 
9 1 (20) - H2O 25 53 60 (R) 
10 1 (20) - DMF/H2Oc 25 60 42 (R) 
11 1 (20) Imidazole (20) CHCl3 25 60 80 (R) 
12 1 (20) PhCO2H CHCl3 25 65 90 (R) 
13 1 (20) 4-ClC6H4CO2H CHCl3 25 78 85 (R) 
14 1 (20) 4-O2NC6H4CO2H CHCl3 25 70 83 (R) 
15 1 (20) 4-MeC6H4CO2H CHCl3 25 67 87 (R) 
16 1 (20) 2,4,6-(Me)3C6H2CO2H CHCl3 25 80 82 (R) 
17  1 (20) 3,4-(MeO)2C6H3CO2H CHCl3 25 73 93 (R) 
18d     1 (20) 3,4-(MeO)2C6H3CO2H CHCl3 25 70 92 (R) 
19 1 (10) 3,4-(MeO)2C6H3CO2H CHCl3 25 60 88 (R) 
20 1 (20) 3,4-(MeO)2C6H3CO2H CHCl3 10 65 90 (R) 
21 ent-1 (20) 3,4-(MeO)2C6H3CO2H CHCl3 25 71 93 (S) 
a Isolated yield after flash chromatography.  
b Enantioselectivities and absolute stereochemistry determined by chiral HPLC (Ref. 16c).  
c 2/1, v/v. 
d 5 equiv of 4a were used. 
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The presence of electron-withdrawing groups in the 
aromatic ring of the acid additive, such as chloro or nitro, 
increased the yield of adduct (R)-6aa, although reduced 
the enantioselectivity of the process  (Table 1, entries  13 
and 14). Therefore, the presence of additives bearing 
electron-releasing groups, such as methyl or methoxy  
was explored (Table 1, entries 15-17). Among them, the 
best results were achieved when 3,4-dimethoxybenzoic 
acid was used as additive (Table 1, entry 17), giving rise 
to γ-nitroketone (R)-6aa in a 93% ee (Table 1, entry 17). 
Although not spectacular, the presence of this acid 
additive was slightly positive for the enantioselectivity, 
but mainly for the chemical yield. 
Keeping the most effective reaction conditions [1 (20 
mol%), 3,4-dimethoxybenzoic acid (20 mol%), CHCl3, 25 
ºC], other parameter changes were explored. Thus, the 
stoichiometry of the reaction was modified and 5 equiv of 
acetophenone was used, no significant changes being 
observed in yield nor stereoselectivity (Table 1, entry 18). 
In addition, the organocatalyst loading was reduced to 10 
mol%, but the former values diminished (Table 1, entry 
19). This also happened when the reaction temperature 
was lowered down to 10 ºC (Table 1, entry 20).    
Expecting to achieve an opposite enantioselection, we 
also performed the reaction using as organocatalyst ent-1, 
which was prepared similarly but using (1R,2R)-
cyclohexane-1,2-diamine as chirality source.17b Using this 
primary amine as organocatalyst (20 mol%) under the 
most effective reaction conditions [3,4-dimethoxybenzoic 
acid (20 mol%), CHCl3, 25 ºC], the expected adduct (S)-
6a was isolated in 93% ee (Table 1, entry 21).   
 
 
 
 Next we explore the scope of this organocatalyzed 
conjugate addition reaction by modifying the ketone and 
the nitroalkene under the most favourable reaction 
conditions [1 (20 mol%), 3,4-dimethoxybenzoic acid (20 
mol%), CHCl3, 25 ºC], the obtained results being 
summarized in Table 2.  
First, we performed the reaction of arylated ketones 4, 
differently substituted on the aromatic ring, to (E)-β-
nitrostyrene (5a). Thus, when an electron-releasing group 
such as a methyl was present at the 3- and 4-position of 
the aromatic ring (4b and 4c), the resulting adducts (R)-
6ba and (R)-6ca were obtained in 86 and 91% ee, 
respectively (Table 2, entries 2 and 3), whereas the 
presence of a 4-methoxy substituent (4d) yielded (R)-6da 
also in 91% ee (Table 2, entry 4). The presence of 
halogens in the aromatic ring, as in the case of ketones 4e-
i, gave rise to the corresponding adducts (R)-6ea-ia, their 
enantioselectivities being in the range 85-88% (Table 2, 
entries 5-9). In addition, the presence of other electron-
withdrawing substituents, such as the trifluoromethyl (4j, 
4k) and nitro (4l) groups, resulted in lower 
enantioselections for the corresponding adducts (R)-6ja, 
(R)-6ka and (R)-6la (Table 2, entries 10-12). Moreover, 
the use of a polyaromatic ketone such as 1-(naphthalen-2-
yl)ethan-1-one (4m) afforded the γ-nitroketone  (R)-6ma 
in 89% ee (Table 2, entry 13), whereas the use of a 
heteroaromatic ketone such as 1-(pyridin-2-yl)ethan-1-
one (4n) yielded the corresponding adduct (R)-6na in a 
much lower 68% ee (Table 2, entry 14). 
We then explore the influence of changing the 
substituent on the nitroalkene 5. Thus, when a 4-methyl 
was present on the aromatic ring (5b), the resulting (R)-
6ab was isolated in 90% ee, a similar value to when a 4-
methoxy group (5c) was present [(R)-6ac, 89% ee] (Table 
2, entries 15 and 16). In addition, when other electron-
releasing systems were present, as in the case of the 
dioxole moiety (5d) and 3,4,5-trimethoxy groups (5e), the 
enantioselectivities for the obtained adducts (R)-6ad and 
(R)-6ae were 90 and 89%, respectively (Table 2, entries 
17 and 18). 
When halogen groups were present on the aromatic 
ring of 5 (5f-i), the corresponding γ-nitroketones (R)-6af-
ai) were isolated with enantioselectivities ranging from 86 
to 93% (Table 2, entries 19-22). Adduct (R)-6ah results 
particularly interesting, as is an intermediate in the 
preparation of the commercial drug phenibut.16h In 
addition, the presence of other electron-withdrawing 
substituents such as the 4-trifluoromethyl  (5j) and 4-nitro 
(5k) afforded adducts (R)-6aj and (R)-6ak in 87 and 88% 
ee, respectively (Table 2, entries 23 and 24). Moreover, 
the presence of a system such as the 2-naphthyl (5l) 
allowed to prepare (R)-6al in 90% ee (Table 2, entry 25), 
and the use of heteroaromatic systems such as a 3-pyridyl 
(5m) and 2-furanyl (5n) yielded γ-nitroketones (R)-6am 
and (S)-6an (no change in the enantioselectivity sense, 
just an effect of the CIP rules),  with enantioselections of 
86 and 96%, respectively (Table 2, entries 26 and 27). 
Finally, we explored the use of organocatalyst 1, under 
the former reaction conditions, in the conjugate addition 
of the simple acetone (5 equiv), to these nitroalkenes 
(Table 2). Thus, when acetone (4o) reacted with (E)-β-
nitrostyrene (5a), the corresponding γ-nitroketone (R)-6oa 
was isolated in  a 92% yield and in 70% ee (Table 2, entry 
28). When a 4-methyl or a 4-methoxy group was present 
in the nitroalkene, the corresponding adducts (R)-6ob and 
(R)-6oc were obtained in 67 and 70% ee, respectively 
(Table 2, entries 29 and 30), whereas the presence of 
halogen groups such as a 4-fluoro and 4-chloro gave rise 
to higher enantioselections of the isolated adducts (R)-6of 
and (R)-6oh, respectively (Table 2, entries 31 and 32). 
However, the reaction with a 4-trifluoromethylated 
nitroalkene (5j) produced a lower enantioselectivity for 
the γ-nitroketone (R)-6oj (Table 2, entry 33), as well as 
when using the 2-naphthyl-nitroalkene 5j (Table 2, entry 
34). Finally, a higher enantioselection for adduct (S)-6on 
(84%) was observed when using a 2-furanyl as substituent 
in the nitroalkene (5n) (Table 2, entry 35). 
       
 Tetrahedron: Asymmetry 
Table 2. Enantioselective addition of ketones to nitroalkenes organocatalyzed by 1. 
 
Entry Ketonea Nitroalkene t (d) Adduct No. Yield (%)b ee (%)c,d 
 R1 No. R2 No.     
1 Ph 4a Ph 5a 5 (R)-6aa 73 93 
2 3-MeC6H4 4b Ph 5a 5 (R)-6ba 70 86 
3 4-MeC6H4 4c Ph 5a 5 (R)-6ca 70 91 
4 4-MeOC6H4 4d Ph 5a 5 (R)-6da 63 91 
5 4-FC6H4 4e Ph 5a 5 (R)-6ea 68 88 
6 3-ClC6H4 4f Ph 5a 5 (R)-6fa 68 85 
7 4-ClC6H4 4g Ph 5a 5 (R)-6ga 70 86 
8 4-BrC6H4 4h Ph 5a 5 (R)-6ha 70 88 
9 4-IC6H4 4i Ph 5a 5 (R)-6ia 67 88 
10 3-F3CC6H4 4j Ph 5a 5 (R)-6ja 71 82 
11 4-F3CC6H4 4k Ph 5a 5 (R)-6ka 68 83 
12 4-O2NC6H4 4l Ph 5a 5 (R)-6la 58 75 
13 2-Naphthyl 4m Ph 5a 5 (R)-6ma 71 89 
14 2-Pyridinyl 4n Ph 5a 5 (R)-6na 85 68 
15 Ph 4a 4-MeC6H4 5b 5 (R)-6ab 70 90 
16 Ph 4a 4-MeOC6H4 5c 5 (R)-6ac 72 89 
17 Ph 4a 3,4-(OCH2O)C6H3 5d 5 (R)-6ad 60 90 
18 Ph 4a 3,4,5-(MeO)3C6H2 5e 5 (R)-6ae 56 89 
19 Ph 4a 4-FC6H4 5f 5 (R)-6af 75 87 
20 Ph 4a 2-ClC6H4 5g 5 (R)-6ag 77 93 
21 Ph 4a 4-ClC6H4 5h 5 (R)-6ah 73 90 
22 Ph 4a 4-BrC6H4 5i 5 (R)-6ai 70 86 
23 Ph 4a 4-F3CC6H4 5j 5 (R)-6aj 68 87 
24 Ph 4a 4-O2NC6H4 5k 5 (R)-6ak 75 88 
25 Ph 4a 2-Naphthyl 5l 5 (R)-6al 69 90 
26 Ph 4a 3-Pyridinyl 5m 5 (R)-6am 70 86 
27 Ph 4a 2-Furanyl 5n 5 (S)-6an 74 96 
28 Me 4o Ph 5a 3 (R)-6oa 92 70 
29 Me 4o 4-MeC6H4 5b 3 (R)-6ob 85 67 
30 Me 4o 4-MeOC6H4 5c 3 (R)-6oc 85 70 
31 Me 4o 4-FC6H4 5f 3 (R)-6of 79 74 
32 Me 4o 4-ClC6H4 5h 3 (R)-6oh 87 78 
33 Me 4o 4-F3CC6H4 5j 3 (R)-6oj 70 69 
34 Me 4o 2-Naphthyl 5l 3 (R)-6ol 71 62 
35 Me 4o 2-Furanyl 5n 3 (S)-6on 78 84 
a 2 equiv of 4a-n were used; 5 equiv of 4o were used.  
b Isolated yield after flash chromatography.  
c Enantioselectivities determined by chiral HPLC.  
d Absolute configuration assigned by the order of elution of the enantiomers in chiral HPLC (See Experimental). 
 
 
 In order to justify the origin and sense of the observed 
enantioselectivity, we carried out theoretical calculations 
on the reactions of acetophenone (4a) and acetone (4o) 
with nitrostyrene 5a, catalyzed by the NHBoc derivative 
1. We made use of different computational methods 
(M06-2X and B3LYP-D3, see the Calculations section), 
and conditions, like the gas phase system and a water 
solvent model, as extreme situations of apolar and very 
polar environments. In fact, the choice of solvent has been 
shown experimentally to have a significant impact on the 
enantioselectivity (Table 1), and we were intrigued by the 
high ee´s that are obtained in chloroform and other apolar 
solvents, while the use of water or DMF has been shown 
to be detrimental for the observed selectivity. 
 Following the literature evidence, and our own 
previous calculations, we assumed that the reaction is 
taking place through the Seebach´s synclinal model20 
where the nitroalkene is approaching the enamine through 
an endo-type transition state (Figure 1, left). In that 
model, the attack from the lower face of the enamine 
(from our point of view) stereo-specifically determines 
the formation of the R product through reaction with the 
Re face of nitrostyrene. Consequently, the approach from 
the upper face of the enamine (not shown) would deliver 
the S product. The exo variant of the reaction would lead 
to opposite results, but according to Seebach´s model and 
our initial calculations, this alternative is not operative 
and can be safely discarded. 
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Figure 1. Seebach´s synclinal model (left) for the reaction 
of the enamine model and nitrostyrene. 
 
 We have previously studied a related reaction 
(enamine + maleimide), which was also catalyzed by 1, 17b 
finding that the polarity of the solvent has an effect on the 
conformation of the catalyst, and more significantly, on 
the differential stabilization of the diastereomeric 
transition states. Thus, in the simplest alternative, the 
electrophile can be activated by an intramolecular H-bond 
with the NHBoc hydrogen of the catalyst (TSAMe-R and 
TSAPh-R, Figure 2). Due to the relative disposition of the 
NH groups of the enamine and the NHBoc moieties, the 
electrophile shows a clear preference for the approach 
through the lower face of the enamine, leading to the 
formation of the R products. This effect is independent of 
the source of the enamine, either coming from acetone or 
acetophenone. 
 
Figure 2. Computed Gibbs Free activation energies for the 
TSA-type transition states in the gas phase and water models. 
 
 The presence of the internal hydrogen bond makes this 
transition state very apolar, and thus, quite insensitive to 
the polarity of the solvent. When computed in the gas 
phase (as the extreme case for an apolar environment), the 
Gibbs Free activation energy was as low as 14.6 kcal/mol 
for acetone derived enamine (TSAMe-R), and 20.3 
kcal/mol for the acetophenone (TSAPh-R). As expected, 
the energies in water are similar to the gas phase, 
increasing slightly to 15.3 kcal/mol for acetone, and 
staying ca 20.0 kcal/mol for acetophenone. 
 A second main approach was found, wherein the 
nucleophile is attacking from the upper face of the 
enamine (Figure 3), in the distal position from the NHBoc 
group, and thus, without the possibility of forming any 
intramolecular H-bond. In TSBMe-S and TSBPh-S, the 
attack takes place from the left side (from our point of 
view in Figure 3) of the enamine, thorough the Si face of 
the nitroalkene (S product), whereas the approach of the 
nitroalkene from the right side of the enamine 
(hypothetical TSC) is strongly disfavoured due to steric 
repulsion with the large Boc group, which is blocking that 
face. We could not actually find any transition state for 
that approach without severely distorting the structure. 
Interestingly, the transition structures in Figure 3 are very 
polar, showing a clear separation of the developing 
positive and negative charges on the enamine and the 
nitroalkene, respectively. This type of situations are very 
sensitive to the environment, highly favoured in polar 
solvents, and specially in protic solvents (water) which 
are able to solvate and activate the electrophile by the 
formation of intermolecular H-bonds. Consequently, the 
computed energies in water (16.9 and 19.3 kcal/mol) are 
lower than in the gas phase (17.8 and 21.7 kcal/mol).  
 
 
Figure 3. Computed Gibbs Free activation energies for 
the TSB-type transition states in the gas phase and water 
models. 
 
 Taking all together, these computational data are able 
to explain the experimental findings. If the reaction is 
performed in an apolar system, the lowest-in-energy 
transition states are TSAMe-R and TSAPh-R, bearing the 
internal H-bond activation, and explaining the highly 
enantioselective formation of the R product. As the 
polarity of the solvent increases, the polar transition states 
(TSB-type, Figure 3) gain relative significance, inducing 
a deleterious effect on the enantioselectivity (Table 1, 
entries 8, 9 and 10). Furthermore, these results also agree 
with the common chemical sense, by which 
intramolecular H-bonds are stronger in apolar solvents, 
while intermolecular H-bonds with surrounding water 
molecules are present in aqueous systems. Finally, 3D 
representations29 of the operative transition states for 
acetophenone in the gas phase and in the water model are 
shown in Figure 4. 
 Tetrahedron: Asymmetry  
nitrostyrene
acetophenone
Boc
nitrostyrene
Boc
acetophenone
TSAPh-R TSBPh-S
 Figure 4. 3-D representation of the transition states for 
the reaction of acetophenone and nitrostyrene       
 
  
3. Conclusions 
We conclude that primary amine-containing 
carbamates, prepared easily by monoprotection of 
enantiomerically pure trans-cyclohexane-1,2-diamines 
with the common Boc, Cbz and Fmoc groups, act as 
organocatalysts in the enantioselective addition of aryl 
ketones to nitroalkenes, leading to enantiomerically 
enriched β-substituted γ-nitroketones. Good yields and 
enantioselectivities can be achieved working in the 
presence of 3,4-dimethoxybenzoic acid as additive. In 
addition, acetone can also be used as pro-nucleophile, 
although affording lower enantioselections. Theoretical 
calculations suggest that the presence of an intramolecular 
H-bond activation of the nitrostyrene with the NHBoc 
moiety of the catalyst is responsible for the preferential 
formation of the R product in apolar solvents like 
chloroform. The partial rupture of the H-bond in polar 
solvents, like water or DMF, induces the formation of a 
more polar transition state (S enantiomer), explaining the 
deleterious effect of the solvent polarity on the 
enantioselectivity of the reaction. 
   
4. Experimental 
4.1. General. All the reagents and solvents were of the 
best grade available and used without further purification. 
IR data were collected with a Nicolet Impact 400D-FT 
spectrometer. The 1H and 13C NMR spectroscopic data 
were recorded at 25 °C with a Bruker AC-300 at 300 and 
75 MHz, respectively, or a Bruker AC-400 at 400 and 101 
MHz, respectively, with TMS as the internal standard. MS 
spectra were registered with an Agilent MS 5973 (GC). 
HRMS analyses were performed with an Agilent 7200 
Accurate-Mass Q-TOF instrument (DIP probe), using 
chemical ionization (methane). Nitroalkenes 5 were 
purchased or prepared according to a reported 
procedure,21 except 5m which was obtained following 
other methododology.22 Absolute configuration for 
adducts 6 was determined according to the described 
order of elution of their enantiomers in chiral HPLC, 
whereas in the case of new compounds it was assigned by 
analogy. In the case of compounds 6ba and 6on, the 
employed HPLC chiral columns are the same than those 
reported in the literature (Chiralpak AS-H and AD-H, 
respectively). It has been assured for the rest of the 
adducts that the employed Chiralpak AS-H column 
maintains the same elution order of the enantiomers than 
when using a Chiralpak AD-H column, but giving cleaner 
determinations in the reaction crude. Reference racemic 
samples of adducts 6 were obtained by performing the 
reaction using an equimolecular mixture of 1 and ent-1 
(20 mol%) as organocatalyst in toluene as solvent at 25 
ºC. 
 
4.2. General Procedure for the Enantioselective 
Conjugate Addition Reaction. To a solution of 1 (8.6 
mg, 0.04 mmol), the nitroalkene (0.2 mmol) and 3,4-
dimethoxybenzoic acid  (7.3 mg, 0.04 mmol) in CHCl3 
(0.5 mL) was added the ketone (0.4 mmol for 4a-n, 74 
µL, 1 mmol for 4o) and the mixture was stirred at 25 ºC 
for the time shown in Table 2. The reaction was quenched 
with HCl 2N (10 mL) and the mixture was extracted with 
AcOEt (3x10 mL). The organic phase was dried over 
MgSO4, and the solvent was evaporated (15 Torr) to get 
the crude product, which was purified by silica gel 
chromatography (n-hexane/AcOEt gradients). 
 Adducts 6 were identified by comparison of their 
spectroscopic data with those of the literature. Their 
enantiomeric excesses were determined by chiral HPLC.  
 
(R)-4-nitro-1,3-diphenylbutan-2-one (6aa).16c White 
solid, mp 88-89 °C; 1H NMR (300 MHz, CDCl3): δH = 
7.92 (dd, J = 8.4, 1.3 Hz, 2H), 7.57 (d, J = 7.4 Hz, 1H), 
7.46 (dd, J = 8.2, 6.9 Hz, 2H), 4.84 (dd, J = 12.5, 6.7 Hz, 
1H), 4.70 (dd, J = 12.4, 7.9 Hz, 1H), 4.29-4.17 (m, 1H), 
3.50 (dd, J = 16.3, 5.0 Hz, 1H), 3.42 (dd, J = 16.3, 6.0 Hz, 
1H) ppm; 13C NMR (75 MHz, CDCl3): δC = 196.8, 
139.1, 136.4, 133.6, 129.1, 128.7, 128.0, 127.9, 127.4, 
79.6, 41.5, 39.3 ppm; HPLC: Chiralpak AS-H , λ = 210 
nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 
8.7 min, tr (major) = 10.3 min.  
 
(R)-4-nitro-3-phenyl-1-(m-tolyl)butan-1-one (6ba).16c 
Colourless oil; 1H NMR (300 MHz, CDCl3): δH = 7.72-
7.70 (m, 2H), 7.40-7.25(m, 7 H), 4.81-4.86(dd, J = 6.8 
Hz, 12.8 Hz, 1H), 4.83 (dd, J = 12.5, 6.6 Hz, 1H), 4.68 
(dd, J = 12.5, 8.1 Hz, 1H), 4.27-4.17 (m, 1H), 3.47 (dd, J 
= 17.9, 6.5 Hz, 1H), 3.40 (dd, J = 17.9, 7.7 Hz, 1H), 2.39 
(s, 3H) ppm; 13C NMR (101 MHz, CDCl3): δC = 197.0, 
139.1, 138.5, 136.3, 134.3, 129.0, 128.5, 128.5, 127.8, 
127.4, 125.2, 79.5, 41.5, 39.2, 21.3 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 7.2 min, tr (major) = 8.9 
min. 
 
(R)-4-nitro-3-phenyl-1-(p-tolyl)butan-1-one (6ca).16e 
Colourless oil; 1H NMR (300 MHz, CDCl3): δH = 7.86-
7.78 (m, 2H), 7.35-7.23 (m, 7H), 4.83 (dd, J = 12.5, 6.5 
Hz, 1H), 4.67 (dd, J = 12.5, 8.1 Hz, 1H), 4.26-4.15 (m, 
1H), 3.45 (dd, J = 17.6, 6.4 Hz, 1H), 3.37 (dd, J = 17.6, 
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7.6 Hz, 1H), 2.40 (s, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δC = 196.4, 144.4, 139.2, 133.8, 129.3, 129.0, 
128.1, 127.8, 127.4, 79.5, 41.3, 39.3, 21.6 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 8.9 min, tr (major) = 10.5 
min. 
 
(R)-1-(4-methoxyphenyl)-4-nitro-3-phenylbutan-1-one 
(6da).16c White solid, mp 90-91 °C; 1H NMR (300 MHz, 
CDCl3): δH = 7.94 (d, J = 9.0 Hz, 4H), 7.38-7.23 (m, 5H), 
6.93 (d, J = 8.9 Hz, 4H), 4.84 (dd, J = 12.5, 6.5 Hz, 1H), 
4.68 (dd, J = 12.5, 8.1 Hz, 1H), 4.27-4.15 (m, 1H), 3.87 
(s, 3H), 3.43 (dd, J = 17.5, 6.4 Hz, 1H), 3.35 (dd, J = 
17.5, 7.6 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δC = 
195.3, 163.8, 139.3, 130.3, 129.4, 129.00, 127.8, 127.4, 
113.8, 79.6, 55.5, 41.1, 39.4 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 18.9 min, tr (major) = 23.1 min. 
 
(R)-1-(4-fluorophenyl)-4-nitro-3-phenylbutan-1-one 
(6ea).23 Colourless oil; 1H NMR (300 MHz, CDCl3): δH = 
7.98-7.93 (m, 2H), 7.37-3.32 (m, 2H), 7.31-7.24 (m, 3H), 
7.16-7.10 (m, 2H), 4.83 (dd, J = 12.4, 6.8 Hz, 1H), 4.69 
(dd, J = 12.4, 7.7 Hz, 1H), 4.27-4.17 (m, 1H), 3.47 (dd, J 
= 17.7, 6.6 Hz, 1H), 3.40 (dd, J = 17.7, 7.3 Hz, 1H) ppm; 
13C NMR (75 MHz, CDCl3): δC = 195.2, 165.6 (d, J = 
254.6 Hz), 138.9, 132.7 (d, J = 2.8 Hz), 130.8 (d, J = 9.3 
Hz), 129.0, 127.8, 127.3, 115.5 (d, J = 21.8 Hz), 79.4, 
41.3, 39.2 ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-
hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 9.4 
min, tr (major) = 11.3 min. 
 
(R)-1-(3-chlorophenyl)-4-nitro-3-phenylbutan-1-one 
(6fa).16e Colourless oil; 1H NMR (400 MHz, CDCl3): δH = 
7.87 (t, J = 1.8 Hz, 1H),  7.53 (ddd, J = 7.9, 2.1, 1.0 Hz, 
1H), 7.39 (t, J = 7.9 Hz, 1H), 7.35-7.31 (m, 2H), 7.30-
7.25 (m, 3H), 4.80 (dd, J = 12.5, 6.8 Hz, 1H), 4.68 (dd, J 
= 12.5, 7.8 Hz, 1H), 4.25-4.17 (m, 1H), 3.46 (dd, J = 17.8, 
6.6 Hz, 1H), 3.40 (dd, J = 17.8, 7.2 Hz, 1H) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 195.5, 138.8, 137.8, 135.0, 
133.4, 130.0, 129.1, 128.1, 127.9, 127.4, 126.0, 79.4, 
41.6, 39.1 ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-
hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 8.5 
min, tr (major) = 10.6 min. 
 
(R)-1-(4-chlorophenyl)-4-nitro-3-phenylbutan-1-one 
(6ga).16c White solid, mp 67-68 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.84 (d, J = 8.7 Hz, 1H), 7.41 (d, J = 8.7 Hz, 
1H), 7.35-7.31 (m, 2H), 7.30-7.24 (m, 3H), 4.81 (dd, J = 
12.5, 6.8 Hz, 1H), 4.68 (dd, J = 12.5, 7.8 Hz, 1H), 4.24-
4.17 (m, 1H), 3.44 (dd, J = 17.7, 6.6 Hz, 1H), 3.39 (dd, J 
= 17.7, 7.3 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3): 
δC = 195.6, 140.00, 138.9, 134.6, 129.4, 129.1, 129.0, 
127.9, 127.4, 79.4, 41.4, 39.2 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 10.5 min, tr (major) = 12.6 min. 
 
(R)-1-(4-bromophenyl)-4-nitro-3-phenylbutan-1-one 
(6ha).16e White solid, mp 86-87 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.76 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 8.7 Hz, 
1H), 7.36-7.29 (m, 2H), 7.28-7.24 (m, 3H), 4.81 (dd, J = 
12.5, 6.8 Hz, 1H), 4.68 (dd, J = 12.5, 7.8 Hz, 1H), 4.24-
4.17 (m, 1H), 3.44 (dd, J = 17.7, 6.5 Hz, 1H), 3.38 (dd, J 
= 17.7, 7.3 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3): 
δC = 195.8, 138.8, 135.0, 132.0, 129.5, 129.1, 128.8, 
127.9, 127.4, 79.4, 41.4, 39.2 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 11.8 min, tr (major) = 14.5 min. 
 
(R)-1-(4-iodophenyl)-4-nitro-3-phenylbutan-1-one 
(6ia).15b White solid, mp 98-99 °C; 1H NMR (300 MHz, 
CDCl3): δH = 7.81 (d, J = 8.7 Hz, 1H), 7.60 (d, J = 8.7 Hz, 
1H), 7.40-7.17 (m, 5H), 4.80 (dd, J = 12.5, 6.8 Hz, 1H), 
4.67 (dd, J = 12.5, 7.8 Hz, 1H), 4.25-4.15 (m, 1H), 3.45 
(dd, J = 17.7, 6.6 Hz, 1H), 3.38 (dd, J = 17.7, 7.3 Hz, 1H) 
ppm; 13C NMR (75 MHz, CDCl3): δC = 196.1, 138.8, 
138.0, 135.5, 129.3, 129.1, 127.9, 127.4, 101.6, 79.4, 
41.3, 39.2 ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-
hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 14.4 
min, tr (major) = 17.9 min. 
 
(R)-4-nitro-3-phenyl-1-(3-(trifluoromethyl)phenyl)-
butan-1-one (6ja). Colourless oil; IR (ATR): ν = 3066, 
2922, 1690, 1550, 1409, 1321, 1167, 1126, 1065 cm-1; 1H 
NMR (400 MHz, CDCl3): δH = 8.10 (d, J = 7.9 Hz, 1H), 
7.83 (d, J = 7.9 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.39-
7.21 (m, 5H), 4.83 (dd, J = 12.5, 7.0 Hz, 1H), 4.71 (dd, J 
= 12.5, 7.6 Hz, 1H), 4.28-4.21 (m, 1H), 3.52 (dd, J = 17.8, 
6.6 Hz, 1H), 3.46 (dd, J = 17.8, 7.1 Hz, 1H) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 195.5, 138.7, 136.8, 131.4 
(q, J = 33.3 Hz), 131.12, 129.9 (q, J = 3.4 Hz), 129.5, 
129.2, 128.0, 127.4, 124.8 (q, J = 3.9Hz), 123.5 (q, J = 
273.7Hz), 79.4, 41.6, 39.2 ppm; MS (EI, 70 ev): m/z (%) 
= 287 (100), 275 (46), 185 (54), 173 (28), 145 (41), 130 
(17), 103 (21), 77 (15); HRMS (CI-CH4): m/z calcd for 
C17H15F3NO3 [M+H]+: 338,0999, found: 338.1005; 
HPLC: Chiralpak AS-H , λ = 210 nm, n-hexane/2-
propanol, 80:20, 1.0 mL/min, tr (minor) = 7.8 min, tr 
(major) = 9.7 min. 
 
(R)-4-nitro-3-phenyl-1-(4-(trifluoromethyl)phenyl)-
butan-1-one (6ka).16g Colourless oil; 1H NMR (300 
MHz, CDCl3): δH = 8.00 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 
8.2 Hz, 2H), 7.37-7.17 (m, 5H), 4.81 (dd, J = 12.5, 7.0 
Hz, 1H), 4.69 (dd, J = 12.5, 7.6 Hz, 1H), 4.27-4.18 (m, 
1H), 3.51 (dd, J = 17.9, 6.7 Hz, 1H), 3.45 (dd, J = 17.9, 
7.1 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δC = 
195.9, 139.0, 138.7, 134.7 (q, J = 32.7 Hz), 129.1, 128.3, 
128.0, 127.4, 125.7 (q, J = 3.6 Hz), 123.4 (q, J = 272.9 
Hz), 79.4, 41.8, 39.2 ppm; HPLC: Chiralpak AS-H , λ = 
210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr 
(minor) = 7.1 min, tr (major) = 8.4 min. 
 
(R)-4-nitro-1-(4-nitrophenyl)-3-phenylbutan-1-one 
(6la).16g Pale yellow solid, mp 91-92 °C; 1H NMR (400 
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MHz, CDCl3): δH = 8.28 (d, J = 8.9 Hz, 1H), 8.05 (d, J = 
8.9 Hz, 1H), 7.37-7.31 (m, 2H), 7.31-7.24 (m, 3H), 4.81 
(dd, J = 12.5, 7.1 Hz, 1H), 4.71 (dd, J = 12.5, 7.5 Hz, 1H), 
4.26-4.19 (m, 1H), 3.55 (dd, J = 17.8, 6.7 Hz, 1H), 3.50 
(dd, J = 17.8, 7.0 Hz, 1H) ppm; 13C NMR (101 MHz, 
CDCl3): δC = 195.4, 140.6, 138.5, 129.1, 129.0, 128.0, 
127.3, 123.9, 79.3, 42.0, 39.1 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 32.8 min, tr (major) = 36.7 min. 
 
(R)-1-(naphthalen-2-yl)-4-nitro-3-phenylbutan-1-one 
(6ma).15b White solid, mp 78-79 °C; 1H NMR (400 MHz, 
CDCl3): δH = 8.41 (s, 1H), 7.96 (dd, J = 8.7, 1.6 Hz, 1H), 
7.93 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.1, 4.1 Hz, 2H), 
7.62-7.52 (m, 2H), 7.38- 7.29 (m, 4H), 7.28-7.25 (m, 1H), 
4.87 (dd, J = 12.5, 6.6 Hz, 1H), 4.72 (dd, J = 12.5, 8.0 Hz, 
1H), 4.32-4.24 (m, 1H), 3.60 (dd, J = 18.3, 7.1 Hz, 1H), 
3.54 (dd, J = 18.3, 8.2 Hz, 1H) ppm; 13C NMR (101 MHz, 
CDCl3): δC = 196.7, 139.1, 135.7, 133.6, 132.4, 129.8, 
129.5, 129.0, 128.7, 128.6, 127.8, 127.6, 127.4, 126.9, 
123.5, 79.6, 41.5, 39.4 ppm; HPLC: Chiralpak AS-H , λ = 
210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr 
(minor) = 10.6 min, tr (major) = 11.9 min. 
 
(R)-4-nitro-3-phenyl-1-(pyridin-2-yl)butan-1-one 
(6na).24 White solid, mp 59-61 °C; 1H NMR (400 MHz, 
CDCl3): δH = 8.65 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.98 
(dt, J = 7.7, 0.9 Hz, 1H), 7.80 (td, J = 7.7, 1.7 Hz, 1H), 
7.46 (ddd, J = 7.7, 4.8, 0.9 Hz, 1H), 7.34-7.28 (m, 4H), 
7.27-7.19 (m, 1H), 4.79 (dd, J = 12.4, 6.7 Hz, 1H), 4.68 
(dd, J = 12.4, 8.3 Hz, 1H), 4.28-4.21 (m, 1H), 3.83 (dd, J 
= 18.2, 7.0 Hz, 1H), 3.62 (dd, J = 18.2, 7.2 Hz, 1H) ppm; 
13C NMR (101 MHz, CDCl3): δC = 198.5, 152.6, 148.9, 
139.2, 136.9, 128.9, 127.6, 127.5, 121.8, 79.8, 40.7, 39.2 
ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-hexane/2-
propanol, 70:30, 1.0 mL/min, tr (minor) = 8.5 min, tr 
(major) = 9.4 min. 
 
(R)-4-nitro-1-phenyl-3-(p-tolyl)butan-1-one (6ab).16c 
White solid, mp 72-73 °C; 1H NMR (400 MHz, CDCl3): 
δH = 7.94-7.88 (m, 2H), 7.60-7.52 (m, 1H), 7.48-7.41 (m, 
2H), 7.19-7.09 (m, 4H), 4.80 (dd, J = 12.4, 6.6 Hz, 1H), 
4.65 (dd, J = 12.4, 8.0 Hz, 1H), 4.22-4.14 (m, 1H), 3.45 
(dd, J = 17.6, 6.4 Hz, 1H), 3.39 (dd, J = 17.6, 7.4 Hz, 1H), 
2.30 (s, 3H) ppm; 13C NMR (101 MHz, CDCl3): δC = 
196.9, 137.5, 136.3, 136.0, 133.5, 129.7, 128.7, 128.0, 
127.2, 79.7, 41.5, 38.9, 21.0 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 7.9 min, tr (major) = 10.1 min. 
 
(R)-3-(4-methoxyphenyl)-4-nitro-1-phenylbutan-1-one 
(6ac).16c White solid, mp 69-70 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.96-7.85 (m, 2H), 7.63-7.52 (m, 1H), 7.47-
7.41 (m, 2H), 7.20 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 
Hz, 2H), 4.79 (dd, J = 12.3, 6.6 Hz, 1H), 4.64 (dd, J = 
12.3, 8.0 Hz, 1H), 4.21-4.14 (m, 1H), 3.77 (s, 1H), 3.45 
(dd, J = 17.6, 6.5 Hz, 1H), 3.39 (dd, J = 17.6, 7.3 Hz, 1H) 
ppm; 13C NMR (101 MHz, CDCl3): δC = 196.9, 159.0, 
136.4, 133.5, 130.9, 128.7, 128.5, 128.0, 114.4, 79.8, 
55.2, 41.6, 38.6 ppm; HPLC: Chiralpak AS-H , λ = 210 
nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 
14.6 min, tr (major) = 17.6 min. 
 
(R)-3-(benzo[d][1,3]dioxol-5-yl)-4-nitro-1-phenyl-
butan-1-one (6ad).23 White solid, mp 82-83 °C; 1H NMR 
(400 MHz, CDCl3): δH = 7.94-7.91 (m, 2H), 7.61-7.54 (m, 
1H), 7.50-7.43 (m, 2H), 6.76 (d, J = 1.1 Hz, 1H), 6.74 (d, 
J = 1.3 Hz, 2H), 5.93 (s, 2H), 4.78 (dd, J = 12.4, 6.5 Hz, 
1H), 4.62 (dd, J = 12.4, 8.1 Hz, 1H), 4.18-4.11 (m, 1H), 
3.44 (dd, J = 17.6, 6.5 Hz, 1H), 3.37 (dd, J = 17.6, 7.4 Hz, 
1H) ppm; 13C NMR (101 MHz, CDCl3): δC = 196.8, 
148.1, 147.1, 136.3, 133.6, 132.7, 128.7, 128.0, 120.7, 
108.7, 107.7, 101.2, 79.7, 41.6, 39.1 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 20.0 min, tr (major) = 
25.9 min. 
 
(R)-4-nitro-1-phenyl-3-(3,4,5-trimethoxyphenyl)butan-
1-one (6ae).16f White solid, mp 142-143 °C; 1H NMR 
(300 MHz, CDCl3): δH = 7.95-7.90 (m, 2H), 7.63-7.54 (m, 
1H), 7.50-7.42 (m, 2H), 4.83 (dd, J = 12.5, 6.6 Hz, 1H), 
4.69 (dd, J = 12.5, 8.0 Hz, 1H), 4.23-4.12 (m, 1H), 3.84 
(s, 6H), 3.81 (s, 3H), 3.47 (dd, J = 17.6, 6.3 Hz, 1H), 3.38 
(dd, J = 17.6, 7.5 Hz, 1H) ppm; 13C NMR (75 MHz, 
CDCl3): δC = 196.9, 153.5, 137.6, 136.4, 134.7, 133.6, 
128.7, 128.0, 104.6, 79.4, 60.7, 56.2, 41.6, 39.6 ppm; 
HPLC: Chiralpak AS-H , λ = 210 nm, n-hexane/2-
propanol, 80:20, 1.0 mL/min, tr (minor) = 14.9 min, tr 
(major) = 17.1 min. 
 
(R)-3-(4-fluorophenyl)-4-nitro-1-phenylbutan-1-one 
(6af).16h Colourless oil; 1H NMR (400 MHz, CDCl3): δH = 
7.95-7.87 (m, 2H), 7.62-7.54 (m, 1H), 7.49-7.42 (m, 2H), 
7.30-7.23 (m, 2H), 7.02 (t, J = 8.7 Hz, 2H), 4.82 (dd, J = 
12.5, 6.5 Hz, 1H), 4.66 (dd, J = 12.5, 8.2 Hz, 1H), 4.26-
4.19 (m, 1H), 3.46 (dd, J = 17.7, 6.7 Hz, 1H), 3.41 (dd, J 
= 17.7, 7.3 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3): 
δC = 196.6, 162.1 (d, J = 246.6 Hz), 136.2, 134.8 (d, J = 
3.2 Hz), 133.6, 129.1 (d, J = 8.1 Hz), 128.7, 128.0, 115.9 
(d, J = 21.5 Hz), 79.5, 41.5, 38.6 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 9.6 min, tr (major) = 11.1 
min.  
 
(R)-3-(2-chlorophenyl)-4-nitro-1-phenylbutan-1-one 
(6ag).16c Colourless oil; 1H NMR (400 MHz, CDCl3): δH 
= 7.94 (dd, J = 8.4, 1.3 Hz, 2H), 7.62-7.54 (m, 1H), 7.49-
7.43 (m, 2H), 7.43-7.39 (m, 1H), 7.31-7.27 (m, 1H), 7.27-
7.18 (m, 2H), 4.89 (dd, J = 12.8, 6.9 Hz, 1H), 4.85 (dd, J 
= 12.8, 6.7, 1H), 4.72-66 (m, 1H), 3.58 (dd, J = 17.9, 7.4 
Hz, 1H), 3.52 (dd, J = 17.9, 6.4 Hz, 1H) ppm; 13C NMR 
(101 MHz, CDCl3): δC = 196.7, 136.2, 133.7, 133.6, 
130.4, 129.0, 128.7, 128.4, 128.0, 127.3, 77.5, 39.8, 36.1 
ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-hexane/2-
propanol, 70:30, 1.0 mL/min, tr (minor) = 8.3 min, tr 
(major) = 9.4 min. 
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(R)-3-(4-chlorophenyl)-4-nitro-1-phenylbutan-1-one 
(6ah).16c White solid, mp 48-49 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.91 (dd, J = 8.4, 1.3 Hz, 2H), 7.62-7.55 (m, 
1H), 7.50-7.44 (m, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.27-
7.21 (m, 2H), 4.81 (dd, J = 12.6, 6.5 Hz, 1H), 4.66 (dd, J 
= 12.6, 8.2 Hz, 1H), 4.25-4.18 (m, 1H), 3.46 (dd, J = 17.8, 
6.7 Hz, 1H), 3.40 (dd, J = 17.8, 7.2 Hz, 1H) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 196.4, 137.6, 136.2, 133.7, 
129.2, 128.8, 128.7, 128.0, 79.3, 41.3, 38.6 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 9.4 min, tr (major) = 11.7 
min. 
 
(R)-3-(4-bromophenyl)-4-nitro-1-phenylbutan-1-one 
(6ai).16e White solid, mp 66-67 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.90 (d, J = 8.4 Hz, 2H), 7.61-7.55 (m, 1H), 
7.49-7.41 (m, 4H), 7.17 (d, J = 8.4 Hz, 2H), 4.81 (dd, J = 
12.6, 6.4 Hz, 1H), 4.65 (dd, J = 12.6, 8.2 Hz, 1H), 4.23-
4.16 (m, 1H), 3.45 (dd, J = 17.8, 6.7 Hz, 1H), 3.40 (dd, J 
= 17.8, 7.2 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3): 
δC = 196.4, 138.1, 136.1, 133.7, 132.1, 129.2, 128.7, 
127.9, 121.7, 79.2, 41.2, 38.7 ppm; HPLC: Chiralpak AS-
H , λ = 210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, 
tr (minor) = 9.8 min, tr (major) = 12.7 min. 
 
(R)-4-nitro-1-phenyl-3-(4-(trifluoromethyl)phenyl)-
butan-1-one (6aj).16g Colourless oil; 1H NMR (300 MHz, 
CDCl3): δH = 7.93-7.89 (m, 2H), 7.61-7.58 (m, 3H), 7.49-
7.42 (m, 4H), 4.86 (dd, J = 12.7, 6.4 Hz, 1H), 4.71 (dd, J 
= 12.7, 8.2 Hz, 1H), 3.51 (dd, J = 17.9, 6.7 Hz, 1H), 3.44 
(dd, J = 17.9, 7.2 Hz, 1H) ppm; 13C NMR (75 MHz, 
CDCl3): δC = 196.3, 143.2, 136.1, 133.8, 130.15 (q, J = 
32.8 Hz), 128.8, 128.0, 126.34, 126.0 (q, J = 3.8 Hz), 
123.85 (q, J = 272.1 Hz), 79.0, 41.2, 39.0 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 6.7 min, tr (major) = 8.0 
min. 
 
(R)-4-nitro-3-(4-nitrophenyl)-1-phenylbutan-1-one 
(6ak).16h White solid, mp 102-103 °C;  1H NMR (300 
MHz, CDCl3): δH = 8.25-8.18 (m, 2H), 7.94-7.88 (m, 2H), 
7.63-7.56 (m, 1H), 7.53-7.40 (m, 4H), 4.89 (dd, J = 12.9, 
6.2 Hz, 1H), 4.75 (dd, J = 12.9, 8.3 Hz, 1H), 4.43-4.35 
(m, 1H), 3.54 (dd, J = 18.0, 6.8 Hz, 1H), 3.47 (dd, J = 
18.0, 7.0 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δC = 
195.9, 147.4, 146.6, 135.9, 133.9, 128.8, 128.6, 128.0, 
124.2, 78.8, 41.0, 38.9 ppm; HPLC: Chiralpak AD-H , λ = 
210 nm, n-hexane/2-propanol, 80:20, 1.0 mL/min, tr 
(minor) = 22.2 min, tr (major) = 36.5 min. 
 
(R)-3-(naphthalen-2-yl)-4-nitro-1-phenylbutan-1-one 
(6al).16c White solid, mp 89-90 °C; 1H NMR (400 MHz, 
CDCl3): δH = 7.91 (dd, J = 8.4, 1.3 Hz, 2H), 7.85-7.74 (m, 
3H), 7.72 (d, J = 1.3 Hz, 1H), 7.58-7.51 (m, 1H), 7.51-
7.35 (m, 5H), 4.89 (dd, J = 12.5, 6.6 Hz, 1H), 4.76 (dd, J 
= 12.5, 8.0 Hz, 1H), 4.43-4.35 (m, 1H), 3.56 (dd, J = 17.7, 
6.4 Hz, 1H), 3.49 (dd, J = 17.7, 7.5 Hz, 1H) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 196.7, 136.5, 136.3, 133.5, 
133.3, 132.8, 128.9, 128.7, 128.0, 127.8, 127.6, 126.5, 
126.4, 126.2, 125.1, 79.5, 41.5, 39.4 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 10.3 min, tr (major) = 
13.1 min. 
 
(R)-4-nitro-1-phenyl-3-(pyridin-3-yl)butan-1-one 
(6am). Colourless oil; IR (ATR): ν = 3035, 2929, 2857, 
1684, 1549, 1428, 1267, 1177, 1024 cm-1; 1H NMR (300 
MHz, CDCl3): δH = 8.62 (d, J = 2.2 Hz, 1H), 8.54 (dd, J = 
4.8, 1.5 Hz, 1H), 7.96-7.88 (m, 2H), 7.66 (dt, J = 8.0, 2.0 
Hz, 1H), 7.62-7.57 (m, 2H), 7.50-7.44 (m, 2H), 7.31-7.28 
(m, 1H), 4.88 (dd, J = 12.8, 6.4 Hz, 1H), 4.73 (dd, J = 
12.8, 8.1 Hz, 1H), 4.27 (dd, J = 14.6, 6.8 Hz, 1H), 3.50 (d, 
J = 6.9 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δC = 
196.1, 149.2, 149.0, 136.1, 135.3, 134.9, 133.8, 128.8, 
128.0, 123.8, 78.9, 41.0, 36.9 ppm; MS (EI, 70 ev): m/z 
(%) = 207 (69), 131 (11), 117 (34), 105 (100), 77 (51), 51 
(17); HRMS (CI-CH4): m/z calcd for C15H15N2O3 
[M+H]+: 271,1077, found: 271.1070; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (major) = 22.0 min, tr (minor) = 
38.2 min. 
 
(S)-3-(furan-2-yl)-4-nitro-1-phenylbutan-1-one 
(6an).16c Colourless oil; 1H NMR (400 MHz, CDCl3): δH 
= 8.01-7.91 (m, 2H), 7.63-7.56 (m, 1H), 7.52-7.44 (m, 
2H), 7.34 (dd, J = 1.9, 0.8 Hz, 1H), 6.29 (dd, J = 3.3, 1.9 
Hz, 1H), 6.19 (d, J = 3.3 Hz, 1H), 4.81 (dd, J = 12.6, 6.1 
Hz, 1H), 4.75 (dd, J = 12.6, 7.3 Hz, 1H), 4.37-4.30 (m, 
1H), 3.53 (dd, J = 17.9, 6.1 Hz, 1H), 3.43 (dd, J = 17.9, 
7.5 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3): δC = 
196.5, 151.9, 142.3, 136.2, 133.6, 128.7, 128.0, 110.5, 
107.1, 77.2, 38.9, 33.1 ppm; HPLC: Chiralpak AS-H , λ = 
210 nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr 
(minor) = 8.7 min, tr (major) = 9.7 min.  
 
(R)-5-nitro-4-phenylpentan-2-one (6oa).25 White solid, 
mp 113-114 °C; 1H NMR (300 MHz, CDCl3): δH = 7.34-
7.19 (5H, m), 4.68 (dd, J = 12.3, 6.9 Hz, 1H), 4.58 (dd, J 
= 12.3, 7.9 Hz, 1H), 4.06-3.96 (m, 1H), 2.90 (d, J = 7.0 
Hz, 2H), 2.09 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): 
δC = 205.4, 138.8, 129.0, 127.8, 127.3, 79.4, 46.0, 39.0, 
30.3 ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-
hexane/2-propanol, 75:25, 1.0 mL/min, tr (minor) = 9.5 
min, tr (major) = 11.4 min. 
 
(R)-5-nitro-4-(p-tolyl)pentan-2-one (6ob).25 White solid, 
mp 66-68 °C; 1H NMR (300 MHz, CDCl3): δH = 7.16-
7.06 (m, 4H), 4.67 (dd, J = 12.2, 6.9 Hz, 1H), 4.57 (dd, J 
= 12.2, 7.7 Hz, 1H), 4.01-3.92 (m, 1H), 2.89 (d, J = 7.1 
Hz, 2H), 2.31 (s, 3H), 2.11 (s, 3H) ppm; 13C NMR (75 
MHz, CDCl3): δC = 205.5, 137.6, 135.7, 129.7, 127.2, 
79.6, 46.2, 38.7, 30.4, 21.0 ppm; HPLC: Chiralpak AS-H , 
λ = 210 nm, n-hexane/2-propanol, 80:20, 1.0 mL/min, tr 
(minor) = 9.4 min, tr (major) = 12.4 min. 
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(R)-4-(4-methoxyphenyl)-5-nitropentan-2-one (6oc).25 
White solid, mp 93-94 °C; 1H NMR (300 MHz, CDCl3): 
δH = 7.13 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7Hz, 2H) 4.66 
(dd, J = 12.2, 6.9 Hz, 1H), 4.55 (dd, J = 12.2, 7.8 Hz, 1H), 
4.00-3.91 (m, 1H), 2.88 (d, J =7.1 Hz, 2H), 3.78 (s, 3H), 
2.11 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): δC = 
205.6, 159.1, 130.6, 128.4, 114.4, 79.7, 55.3, 46.3, 38.4, 
30.4 ppm; HPLC: Chiralpak AS-H , λ = 210 nm, n-
hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 15.9 
min, tr (major) = 29.1 min. 
 
(R)-4-(4-fluorophenyl)-5-nitropentan-2-one (6of).26 
White solid, mp 81-82 °C; 1H NMR (300 MHz, CDCl3): 
δH = 7.22-7.18 (m, 2H), 7.04-6.99 (m, 2H), 4.68 (dd, J = 
12.4, 6.6 Hz, 1H), 4.57 (dd, J = 12.4, 7.9 Hz, 1H), 4.05-
3.95 (m, 1H), 2.90 (d, J = 7.0 Hz, 2H), 2.12 (s, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δC = 205.1, 162.2 (d, J = 
246.7 Hz), 134.6 (d, J = 3.4 Hz), 129.0 (d, J = 8.2 Hz), 
115.97 (d, J = 21.6 Hz), 79.4, 46.1, 38.3, 30.3 ppm; 
HPLC: Chiralpak AS-H , λ = 210 nm, n-hexane/2-
propanol, 70:30, 1.0 mL/min, tr (minor) = 9.2 min, tr 
(major) = 11.8 min. 
 
(R)-4-(4-chlorophenyl)-5-nitropentan-2-one (6oh).25 
White solid, mp 90-92 °C; 1H NMR (300 MHz, CDCl3): 
δH = 7.31 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 8.5 Hz, 2H), 
4.68 (dd, J = 12.4, 6.6 Hz, 1H), 4.57 (dd, J = 12.4, 7.9 Hz, 
1H), 4.04-3.96 (m, 1H), 2.90 (d, J = 7.0 Hz, 2H), 2.13 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δC = 205.0, 137.3, 
133.8, 129.2, 128.8, 79.2, 45.9, 38.4, 30.4 ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 11.2 min, tr (major) = 
15.5 min. 
 
(R)-5-nitro-4-(4-(trifluoromethyl)phenyl)pentan-2-one 
(6oj).27 Colourless oil; 1H NMR (400 MHz, CDCl3): δH = 
7.60 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 4.73 
(dd, J = 12.6, 6.5 Hz, 1H), 4.62 (dd, J = 12.6, 8.0 Hz, 1H), 
4.14-4.03 (m, 1H), 2.94 (dd, J = 6.9, 0.9 Hz, 2H), 2.14 (s, 
3H) ppm; 13C NMR (101 MHz, CDCl3): δC = 204.7, 
142.9, 130.2 (q, J = 32.8 Hz), 127.9, 126.0, 123.8 (d, J = 
272.2 Hz), 78.8, 45.8, 38.6, 30.3ppm; HPLC: 
Chiralpak AS-H , λ = 210 nm, n-hexane/2-propanol, 
70:30, 1.0 mL/min, tr (minor) = 6.5 min, tr (major) = 7.8 
min. 
 
(R)-4-(naphthalen-2-yl)-5-nitropentan-2-one (6ol).27 
White solid, mp 101-103 °C; 1H NMR (300 MHz, 
CDCl3): δH = 7.86-7.78 (m, 3H), 7.68 (d, J = 1.5 Hz, 1H), 
7.53-7.45 (m, 2H), 7.34 (dd, J = 8.5, 1.8 Hz, 1H), 4.78 
(dd, J = 12.4, 6.9 Hz, 1H), 4.70 (dd, J = 12.4, 7.7 Hz, 1H), 
4.25-4.14 (m, 1H), 3.00 (d, J = 7.0 Hz, 2H), 2.13 (s, 3H); 
13C NMR: (75 MHz, CDCl3): δC = 205.3, 136.1, 133.3, 
132.8, 128.9, 127.8, 127.6, 126.5, 126.2, 125.0, 79.3, 
46.1, 39.1, 30.4 ppm; HPLC: Chiralpak AS-H , λ = 210 
nm, n-hexane/2-propanol, 70:30, 1.0 mL/min, tr (minor) = 
10.4 min, tr (major) = 14.4 min. 
 
(S)-4-(furan-2-yl)-5-nitropentan-2-one (6on).25 
Colourless oil; 1H NMR (300 MHz, CDCl3): δH = 7.35-
7.33 (m, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.15 (d, J = 
3.3 Hz, 1H), 4.68 (dd, J = 6.6, 1.6 Hz, 2H), 4.15-406 (m, 
1H), 2.94 (dd, J = 8.3, 7.0 Hz, 2H), 2.18 (s, 3H) ppm; 13C 
NMR (75 MHz, CDCl3): δC = 205.0, 151.6, 142.3, 110.5, 
107.1, 77.2, 43.5, 32.9, 30.2 ppm; HPLC: Chiralpak AD-
H , λ = 210 nm, n-hexane/2-propanol, 90:10, 1.0 mL/min, 
tr (major) = 26.4 min, tr (minor) = 29.3 min.  
 
4.3. Calculations. The structures were optimized by using 
density functional theory (DFT) with the B3LYP28 and the 
6-31G* basis set as implemented in Gaussian 09.29 The 
structures were re-optimized at M06-2X/6-311+G** level 
of theory30 on the previously optimized structures,31 
including polarization functions for better description of 
hydrogen bond activations and to better account for the 
dispersion forces of such large systems. Besides, solvation 
factors were introduced with the IEF-PCM method,32 
using water as indicated in the text and figures. 
We also performed single-point calculations at 
B3LYP-D3/6-311+G** level of theory, including 
Grimme´s dispersion with the original D3 damping 
function, and the relative values were similar to those of 
the M06-2X energies.33 The stationary points were 
characterized by frequency calculations in order to verify 
that they have the right number of imaginary frequencies. 
The intrinsic reaction coordinates (IRC)34 were followed 
to verify the energy profiles connecting each TS to the 
correct associated local minima. 3D structures were 
drawn using the CyL view software.35 
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